

## ASX ANNOUNCEMENT

15 June 2023

### S3 Clinical Trial Update

---

**15 June 2023** –As expected, Cann Group Limited (ASX: CAN) (**Cann** or the **Company**) has received formal notification from Haleon Australia Pty Ltd (“Haleon”) regarding their intention to terminate the Option and Evaluation Agreement covering the Company’s S3 clinical trial. Preliminary trial results announced by the Company on 19 January 2023 concluded that the primary end-points did not show a statistically superior response when compared to the placebo.

The termination will take effect on 7 September 2023. During the termination period Haleon and the Company will continue discussions regarding other potential opportunities. The Company will update the market as these discussions progress.

**Authorised for release by Deborah Ambrosini, Company Secretary, Cann Group Limited.**

**For all other information please contact:**

Peter Koetsier  
CEO  
Cann Group Limited  
+61 3 9095 7088  
[contact@canngrouponlimited.com](mailto:contact@canngrouponlimited.com)

Deborah Ambrosini  
CFO and Company Secretary  
Cann Group Limited  
+61 3 9095 7088  
[deborah.ambrosini@canngrouponlimited.com](mailto:deborah.ambrosini@canngrouponlimited.com)

#### **About Cann Group**

Cann Group Limited (ABN 25 603 949 739) is enhancing patients’ lives by developing, producing, and supplying innovative cannabis medicines. The Company has built world-class research, cultivation and GMP manufacturing facilities in Melbourne, and a state-of-the-art large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. Cann Group supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. Cann Group also owns Satipharm and its patent-protected capsule technology.

**Learn more at:** [www.canngrouponlimited.com](http://www.canngrouponlimited.com) | [www.satipharm.com](http://www.satipharm.com)